NCT06511765 Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 40 participants in total. It began in 2026-03-24 with a primary completion date of 2026-09-04.

Brief Summary

This study concerns the treatment of recent lumbago and aims to evaluate the efficacy of an anesthetic block of the erector spinae muscles combining ropivacaine and dexamethasone. This treatment is routinely used in several institutions in France, but has never been the subject of a randomized placebo-controlled study to assess its efficacy at D4 of treatment. The BLOCLOMB comparative, randomized, double-blind study aims to validate the efficacy, over the first 4 days, of anesthetic blocks of the erector spinae muscles, during recent lumbago, on the pain of muscular contractures.

Eligibility Criteria

Inclusion Criteria: 1. Patient with lumbago lasting less than 7 days despite analgesic / NSAID treatment. 2. Patient with NS pain \> 6 3. Patient with Oswestry score \> or equal to 30 4. Patient informed of the trial and having signed the informed consent form prior to any trial-specific procedure, 5. Patient willing and able to undergo all planned examinations and procedures in compliance with the clinical trial protocol, 6. Patient affiliated to a social security or any health insurance. Exclusion Criteria: 1. Presence of "red flag" (non-disc lumbago): * Motor deficit or signs of horsetail irritation * Inflammatory pain waking up in the 2nd half of the night * Tumoral context * Infectious context or fever * Altered general condition * Traumatic context * Osteoporotic context 2. Risk of infection 3. Patient with poor local skin condition 4. Patient on AVK or anti-Xa anticoagulation, or bleeding disorder (antiaggregants authorized) 5. Patients with hypersensitivity to Ropivacaine or any of its excipients: Sodium chloride, hydrochloric acid sodium hydroxide 6. Patient with sciatica 7. Patient with chronic respiratory insufficiency 8. Patient with cardiac rhythm disorders 9. Pregnant or breastfeeding woman or woman refusing effective contraception 10. Patient deprived of liberty or under legal protection (guardianship or curator) 11. Patient participating in another clinical research protocol involving a drug or medical device 12. Patient unable to follow the protocol, as judged by the investigator 13. Patient refusing to participate in the study

Contact & Investigator

Frequently Asked Questions

Related Trials